Yahoo Finance Indiva Third Quarter 2022 Earnings: Misses Expectations
Indiva (CVE:NDVA) Third Quarter 2022 Results
Key Financial Results
Revenue: CA$8.09m (up 4.8% from 3Q 2021).
Net loss: CA$2.57m (loss narrowed by 60% from 3Q 2021).
CA$0.018 loss per share (improved from CA$0.047 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Indiva Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 100%.
Looking ahead, revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are up 7.4% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 3 warning signs for Indiva (1 is a bit concerning!) that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
